Mapi Pharma

Formulations That Meet Unmet Patient Needs

Focused on long acting
depot injections

Developing Finished Dosage Forms and a Portfolio of APIs

Fully integrated GMP
manufacturing facilities

Pipeline of Multiple Late Stage Products

In Phase III for RMS and Phase II for
PPMS for treating MS

We are a clinical stage pharmaceutical company, developing complex active pharmaceutical ingredients.

Focus

Our main focus is on developing long acting depot injectable drugs.

Programs

Our lead programs are GA Depot for treating various forms of MS and long acting Pregabalin (Lyrica^®) for pain.

Latest News

Mapi Pharma to Present Late Breaking Poster Presentation on GA Depot for Treating Primary Progressive Forms of Multiple Sclerosis at CMSC 2022 Annual Meeting

May 31, 2022

Interim analysis of Phase IIa study of GA Depot in PPMS will be presented NESS ZIONA, Israel – May 31, 2022 – Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting depot injectable...

Mapi Pharma to Present Posters on GA Depot for Treating Relapsing Forms of Multiple Sclerosis (MS) and Primary Progressive Forms of Multiple Sclerosis at the American Academy of Neurology (AAN) 2022 Annual Meeting

March 31, 2022

NESS ZIONA, Israel – March 31, 2022 – Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting depot injectable solutions mainly for neurological indications, announced today that two...